Pain Management

At Anesiva, we have dedicated ourselves to the development and commercialization of new therapies for pain management because we believe there is a significant unmet medical need for new treatment options in this area.

Current pain management options are often less than optimal given their limited efficacy, inconvenient administration, long onset of action, limited duration of activity, adverse reactions and/or tendency to cause physical dependence.

With increased competition among hospitals for patients, and increased focus on patient satisfaction to attract patients, we have found that many hospitals in the United States now strive to create “pain-free” environments, and reducing pain is quickly becoming a priority for hospital emergency departments. We believe that this creates a favorable environment for the adoption of our pain medicines.

Please click on the links below for more information regarding the specific types of pain addressed by our lead product, Adlea.

Adlea™:

• In two pivotal Phase 3 trials for the management of acute pain following orthopedic surgery (including surgeries such as total knee replacement and bunionectomy)
• Musculoskeletal pain (including osteoarthritis and tendonitis)
• Trauma-induced neuropathic pain (including interdigital neuroma)